vs
百利高（PRGO）与RXO, Inc.（RXO）财务数据对比。点击上方公司名可切换其他公司
RXO, Inc.的季度营收约是百利高的1.3倍（$1.5B vs $1.1B），RXO, Inc.净利率更高（-3.1% vs -127.8%，领先124.7%），百利高同比增速更快（-2.5% vs -11.9%），百利高自由现金流更多（$148.6M vs $-9.0M），过去两年RXO, Inc.的营收复合增速更高（26.8% vs 1.3%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
RXO是总部位于美国的头部运输及物流解决方案供应商，核心业务覆盖货运经纪、大件商品最后一公里配送、运输管理服务与全链路供应链优化支持，主要服务北美制造业、零售业及电商领域的客户。
PRGO vs RXO — 直观对比
营收规模更大
RXO
是对方的1.3倍
$1.1B
营收增速更快
PRGO
高出9.4%
-11.9%
净利率更高
RXO
高出124.7%
-127.8%
自由现金流更多
PRGO
多$157.6M
$-9.0M
两年增速更快
RXO
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.5B |
| 净利润 | $-1.4B | $-46.0M |
| 毛利率 | 32.6% | — |
| 营业利润率 | -116.0% | -2.9% |
| 净利率 | -127.8% | -3.1% |
| 营收同比 | -2.5% | -11.9% |
| 净利润同比 | -3093.9% | -84.0% |
| 每股收益（稀释后） | $-10.23 | $-0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORXO
| Q4 25 | $1.1B | $1.5B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.1B | $1.7B | ||
| Q3 24 | $1.1B | $1.0B | ||
| Q2 24 | $1.1B | $930.0M | ||
| Q1 24 | $1.1B | $913.0M |
净利润PRGORXO
| Q4 25 | $-1.4B | $-46.0M | ||
| Q3 25 | $7.5M | $-14.0M | ||
| Q2 25 | $-8.4M | $-9.0M | ||
| Q1 25 | $-6.4M | $-31.0M | ||
| Q4 24 | $-44.4M | $-25.0M | ||
| Q3 24 | $-21.0M | $-243.0M | ||
| Q2 24 | $-108.4M | $-7.0M | ||
| Q1 24 | $2.0M | $-15.0M |
毛利率PRGORXO
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — | ||
| Q1 24 | 33.1% | — |
营业利润率PRGORXO
| Q4 25 | -116.0% | -2.9% | ||
| Q3 25 | 7.0% | -0.5% | ||
| Q2 25 | 4.3% | — | ||
| Q1 25 | 4.5% | -2.1% | ||
| Q4 24 | 10.0% | -1.4% | ||
| Q3 24 | 7.4% | -1.9% | ||
| Q2 24 | -2.5% | — | ||
| Q1 24 | -5.1% | -1.3% |
净利率PRGORXO
| Q4 25 | -127.8% | -3.1% | ||
| Q3 25 | 0.7% | -1.0% | ||
| Q2 25 | -0.8% | -0.6% | ||
| Q1 25 | -0.6% | -2.2% | ||
| Q4 24 | -3.9% | -1.5% | ||
| Q3 24 | -1.9% | -23.4% | ||
| Q2 24 | -10.2% | -0.8% | ||
| Q1 24 | 0.2% | -1.6% |
每股收益（稀释后）PRGORXO
| Q4 25 | $-10.23 | $-0.28 | ||
| Q3 25 | $0.05 | $-0.08 | ||
| Q2 25 | $-0.06 | $-0.05 | ||
| Q1 25 | $-0.05 | $-0.18 | ||
| Q4 24 | $-0.32 | $-0.17 | ||
| Q3 24 | $-0.15 | $-1.81 | ||
| Q2 24 | $-0.79 | $-0.06 | ||
| Q1 24 | $0.01 | $-0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $17.0M |
| 总债务越低越好 | — | $387.0M |
| 股东权益账面价值 | $2.9B | $1.5B |
| 总资产 | $8.5B | $3.3B |
| 负债/权益比越低杠杆越低 | — | 0.25× |
8季度趋势，按日历期对齐
现金及短期投资PRGORXO
| Q4 25 | — | $17.0M | ||
| Q3 25 | $432.1M | $25.0M | ||
| Q2 25 | $454.2M | $18.0M | ||
| Q1 25 | $409.9M | $16.0M | ||
| Q4 24 | $558.8M | $35.0M | ||
| Q3 24 | $1.5B | $55.0M | ||
| Q2 24 | $542.8M | $7.0M | ||
| Q1 24 | $658.5M | $7.0M |
总债务PRGORXO
| Q4 25 | — | $387.0M | ||
| Q3 25 | — | $387.0M | ||
| Q2 25 | — | $387.0M | ||
| Q1 25 | — | $387.0M | ||
| Q4 24 | — | $351.0M | ||
| Q3 24 | — | $352.0M | ||
| Q2 24 | — | $370.0M | ||
| Q1 24 | — | $351.0M |
股东权益PRGORXO
| Q4 25 | $2.9B | $1.5B | ||
| Q3 25 | $4.4B | $1.6B | ||
| Q2 25 | $4.5B | $1.6B | ||
| Q1 25 | $4.4B | $1.6B | ||
| Q4 24 | $4.3B | $1.6B | ||
| Q3 24 | $4.6B | $1.7B | ||
| Q2 24 | $4.5B | $579.0M | ||
| Q1 24 | $4.7B | $582.0M |
总资产PRGORXO
| Q4 25 | $8.5B | $3.3B | ||
| Q3 25 | $10.1B | $3.2B | ||
| Q2 25 | $10.1B | $3.2B | ||
| Q1 25 | $9.8B | $3.3B | ||
| Q4 24 | $9.6B | $3.4B | ||
| Q3 24 | $11.2B | $3.4B | ||
| Q2 24 | $10.4B | $1.8B | ||
| Q1 24 | $10.6B | $1.8B |
负债/权益比PRGORXO
| Q4 25 | — | 0.25× | ||
| Q3 25 | — | 0.24× | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.24× | ||
| Q4 24 | — | 0.22× | ||
| Q3 24 | — | 0.21× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.60× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $7.0M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $-9.0M |
| 自由现金流率自由现金流/营收 | 13.4% | -0.6% |
| 资本支出强度资本支出/营收 | 2.4% | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | $-8.0M |
8季度趋势，按日历期对齐
经营现金流PRGORXO
| Q4 25 | $175.4M | $7.0M | ||
| Q3 25 | $51.7M | $23.0M | ||
| Q2 25 | $75.9M | $23.0M | ||
| Q1 25 | $-64.5M | $-2.0M | ||
| Q4 24 | $312.6M | $-7.0M | ||
| Q3 24 | $42.2M | $-7.0M | ||
| Q2 24 | $9.5M | $-5.0M | ||
| Q1 24 | $-1.4M | $7.0M |
自由现金流PRGORXO
| Q4 25 | $148.6M | $-9.0M | ||
| Q3 25 | $29.8M | $9.0M | ||
| Q2 25 | $56.7M | $9.0M | ||
| Q1 25 | $-90.0M | $-17.0M | ||
| Q4 24 | $274.9M | $-19.0M | ||
| Q3 24 | $15.1M | $-18.0M | ||
| Q2 24 | $-18.9M | $-16.0M | ||
| Q1 24 | $-26.5M | $-4.0M |
自由现金流率PRGORXO
| Q4 25 | 13.4% | -0.6% | ||
| Q3 25 | 2.9% | 0.6% | ||
| Q2 25 | 5.4% | 0.6% | ||
| Q1 25 | -8.6% | -1.2% | ||
| Q4 24 | 24.2% | -1.1% | ||
| Q3 24 | 1.4% | -1.7% | ||
| Q2 24 | -1.8% | -1.7% | ||
| Q1 24 | -2.4% | -0.4% |
资本支出强度PRGORXO
| Q4 25 | 2.4% | 1.1% | ||
| Q3 25 | 2.1% | 1.0% | ||
| Q2 25 | 1.8% | 1.0% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 3.3% | 0.7% | ||
| Q3 24 | 2.5% | 1.1% | ||
| Q2 24 | 2.7% | 1.2% | ||
| Q1 24 | 2.3% | 1.2% |
现金转化率PRGORXO
| Q4 25 | — | — | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RXO
| Retail Sector | $546.0M | 37% |
| Last Mile | $298.0M | 20% |
| Food And Beverage Sector | $225.0M | 15% |
| Other Sector | $185.0M | 13% |
| Managed Transportation | $133.0M | 9% |
| Automotive Sector | $93.0M | 6% |
